Retatrutide is a novel glucagon-like peptide-1 receptor activator. This pharmaceutical has shown efficacy in treating type 2 diabetes. By mimicking the actions of naturally occurring GLP-1, Retatrutide enhances insulin secretion and suppresses glucagon release, ultimately leading to better blood sugar control. Clinical trials have demonstrated that